251 related articles for article (PubMed ID: 22191778)
1. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells.
Navarro G; Sawant RR; Biswas S; Essex S; Tros de Ilarduya C; Torchilin VP
Nanomedicine (Lond); 2012 Jan; 7(1):65-78. PubMed ID: 22191778
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
[TBL] [Abstract][Full Text] [Related]
3. Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors.
Essex S; Navarro G; Sabhachandani P; Chordia A; Trivedi M; Movassaghian S; Torchilin VP
Gene Ther; 2015 Mar; 22(3):257-266. PubMed ID: 25354685
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Small Interfering RNA Delivery via Arginine-Rich Polyethylenimine-Based Polyplex in Metastatic and Doxorubicin-Resistant Breast Cancer Cells.
Lu S; Morris VB; Labhasetwar V
J Pharmacol Exp Ther; 2019 Sep; 370(3):902-910. PubMed ID: 30940690
[TBL] [Abstract][Full Text] [Related]
5. Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.
Kobayashi E; Iyer AK; Hornicek FJ; Amiji MM; Duan Z
Clin Orthop Relat Res; 2013 Mar; 471(3):915-25. PubMed ID: 23011844
[TBL] [Abstract][Full Text] [Related]
6. Delivery of siRNA by MRI-visible nanovehicles to overcome drug resistance in MCF-7/ADR human breast cancer cells.
Lin G; Zhu W; Yang L; Wu J; Lin B; Xu Y; Cheng Z; Xia C; Gong Q; Song B; Ai H
Biomaterials; 2014 Nov; 35(35):9495-507. PubMed ID: 25155545
[TBL] [Abstract][Full Text] [Related]
7. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
[No Abstract] [Full Text] [Related]
8. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.
Meng H; Liong M; Xia T; Li Z; Ji Z; Zink JI; Nel AE
ACS Nano; 2010 Aug; 4(8):4539-50. PubMed ID: 20731437
[TBL] [Abstract][Full Text] [Related]
9. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.
Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE
ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892
[TBL] [Abstract][Full Text] [Related]
10. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Gu J; Fang X; Hao J; Sha X
Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
[TBL] [Abstract][Full Text] [Related]
11. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
[TBL] [Abstract][Full Text] [Related]
12. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.
Patil YB; Swaminathan SK; Sadhukha T; Ma L; Panyam J
Biomaterials; 2010 Jan; 31(2):358-65. PubMed ID: 19800114
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
14. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
15. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
16. Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy.
Zhang CG; Zhu WJ; Liu Y; Yuan ZQ; Yang SD; Chen WL; Li JZ; Zhou XF; Liu C; Zhang XN
Sci Rep; 2016 Mar; 6():23859. PubMed ID: 27030638
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression.
Huang HY; Kuo WT; Chou MJ; Huang YY
J Biomed Mater Res A; 2011 Jun; 97(3):330-8. PubMed ID: 21465641
[TBL] [Abstract][Full Text] [Related]
18. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).
Zhang X; Li J; Qiu Z; Gao P; Wu X; Zhou G
Cancer Biol Ther; 2009 Jun; 8(12):1117-21. PubMed ID: 19502811
[TBL] [Abstract][Full Text] [Related]
19. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
Dönmez Y; Gündüz U
Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Antitumor Activity of Folate-Conjugated Cholic Acid-Polyethylenimine Micelles for the Codelivery of Doxorubicin and siRNA to Colorectal Adenocarcinomas.
Amjad MW; Amin MC; Katas H; Butt AM; Kesharwani P; Iyer AK
Mol Pharm; 2015 Dec; 12(12):4247-58. PubMed ID: 26567518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]